Disc Medicine Pill Succeeds in Late Stage Trial
Disc Medicine reported successful late stage trial results for its experimental pill treating a rare sun allergy disorder. The treatment significantly reduced symptoms and increased pain free sunlight exposure time for patients. The company plans to seek FDA approval by the end of the year.
Xurve View
Insights:
Xurve View
Disc Medicine reported on Monday morning that its experimental pill for a rare sun allergy helped patients tolerate sunlight without pain, driving shares up 35% in early trading. The late-stage trial success clears the path for the company to resubmit its application to the United States Food and Drug Administration. The new data supports a potential approval and launch by mid-2027.
